General Enrollment Period (GEP)

The General Enrollment Period (GEP) is a period when individuals who didn't enroll in Medicare Part B during their Initial Enrollment Period (IEP) can enroll. The GEP occurs from January 1 to March 31 of each year, and coverage will start on July 1 of that year.

Here are some key features of the General Enrollment Period:

• The GEP is available for individuals who did not enroll in Medicare Part B during their Initial Enrollment Period (IEP), which is the seven-month period surrounding the individual's 65th birthday.

• During the GEP, individuals can enroll in Medicare Part B, but they may have to pay a late enrollment penalty, which is an additional monthly premium that is added to their Medicare Part B premium for as long as they have Medicare Part B.

• Coverage for those who enroll during the GEP will start on July 1 of that year.

• Individuals who missed their IEP and the GEP may be able to enroll in Medicare Part B during a Special Enrollment Period (SEP) if they meet certain criteria, such as losing group health coverage.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.